178 related articles for article (PubMed ID: 25091693)
1. Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
3. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Havrilesky LJ; Scott AL; Davidson BA; Secord AA; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2021 Aug; 162(2):440-446. PubMed ID: 34053748
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
[TBL] [Abstract][Full Text] [Related]
5. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
Lee JY; Kim K; Lee YS; Kim HY; Nam EJ; Kim S; Kim SW; Kim JW; Kim YT
Gynecol Oncol; 2016 Dec; 143(3):622-627. PubMed ID: 27771167
[TBL] [Abstract][Full Text] [Related]
6. Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
Bridges JF; la Cruz M; Pavilack M; Flood E; Janssen EM; Chehab N; Fernandes AW
Future Oncol; 2019 Dec; 15(34):3895-3907. PubMed ID: 31621403
[No Abstract] [Full Text] [Related]
7. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.
Bridges JF; Mohamed AF; Finnern HW; Woehl A; Hauber AB
Lung Cancer; 2012 Jul; 77(1):224-31. PubMed ID: 22369719
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
PEBC’s Ovarian Oncology Guidelines Group
Gynecol Oncol; 2017 Aug; 146(2):392-398. PubMed ID: 28601379
[TBL] [Abstract][Full Text] [Related]
9. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma.
Wong MK; Mohamed AF; Hauber AB; Yang JC; Liu Z; Rogerio J; Garay CA
J Med Econ; 2012; 15(6):1139-48. PubMed ID: 22808923
[TBL] [Abstract][Full Text] [Related]
10. Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.
Donovan HS; Hagan TL; Campbell GB; Boisen MM; Rosenblum LM; Edwards RP; Bovbjerg DH; Horn CC
Support Care Cancer; 2016 Jun; 24(6):2635-42. PubMed ID: 26746209
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment.
Amaador K; Nieuwkerk PT; Minnema MC; Kersten MJ; Vos JMI
Cancer Med; 2023 Feb; 12(3):3376-3386. PubMed ID: 35880731
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
14. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
[TBL] [Abstract][Full Text] [Related]
15. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.
Sun CC; Bodurka DC; Weaver CB; Rasu R; Wolf JK; Bevers MW; Smith JA; Wharton JT; Rubenstein EB
Support Care Cancer; 2005 Apr; 13(4):219-27. PubMed ID: 15538640
[TBL] [Abstract][Full Text] [Related]
16. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
17. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment.
Bullen A; Ryan M; Ennis H; Gray E; Loría-Rebolledo LE; McIntyre M; Hall P
BMJ Open; 2024 Apr; 14(4):e076798. PubMed ID: 38684245
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
